FDA clears AstraZeneca’s Imfinzi-BCG combo for high-risk bladder cancer

USA—The FDA has approved AstraZeneca’s PD-L1 inhibitor Imfinzi for use in combination therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) patients who have not had Bacillus Calmette-Guérin (BCG) therapy.

The approval pairs Imfinzi with BCG induction and maintenance therapy, marking the first immunotherapy-based combination cleared in this setting, according to AstraZeneca’s May 28 announcement.

The decision expands Imfinzi’s bladder cancer footprint beyond its earlier approval in muscle-invasive bladder cancer (MIBC), where it is used with chemotherapy agents’ gemcitabine and cisplatin before surgery and as a monotherapy afterward.

Phase 3 Data Support Durable Clinical Benefit

AstraZeneca said the approval is supported by a phase 3 clinical trial that evaluated one year of Imfinzi treatment alongside BCG therapy.

The study showed a 32% reduction in the risk of high-risk disease recurrence, progression, or death compared with BCG alone.

With a median follow-up of 61 months, investigators observed an early and sustained improvement in disease-free survival, beginning within four months of treatment initiation.

The regimen also demonstrated consistent benefit across key patient subgroups, strengthening its clinical profile in early-stage bladder cancer management.

Clinical Significance in High-Risk NMIBC

The combination represents a major shift in treatment for BCG-naïve, high-risk NMIBC patients, a group with limited therapeutic advances over the past three decades.

According to investigator Neal Shore, many patients in this category experience repeated tumor recurrence, often requiring multiple surgeries or eventual bladder removal.

AstraZeneca estimates that more than 31,000 patients in the United States received treatment for high-risk NMIBC in 2024.

The company also notes that up to 80% of high-risk patients may experience recurrence within five years, underscoring the unmet clinical need.

Expanding Bladder Cancer Pipeline and Recent Data

The approval adds momentum to AstraZeneca’s broader bladder cancer program, which has recently delivered multiple phase 3 successes.

Last week, the company reported positive results from its Volga trial in muscle-invasive bladder cancer, where Imfinzi combined with Pfizer and Astellas Pharma’s antibody-drug conjugate Padcev showed improvements in event-free and overall survival compared with standard care.

Competitive Pressure from Keytruda

The bladder cancer market remains highly competitive, particularly against Merck & Co.’s Keytruda, which has maintained a dominant position in oncology.

Keytruda generated US$32 billion in 2025 and US$8 billion in the first quarter of 2026, supported by multiple bladder cancer approvals, including combination use with Padcev and perioperative treatment settings for MIBC and NMIBC.

Meanwhile, Imfinzi continues to expand its commercial momentum, generating US$6.1 billion in sales in 2025 and reaching US$1.7 billion in the first quarter of 2026, reflecting steady demand growth across oncology indications.